Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.

@article{Rodgers1998DesignAS,
  title={Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.},
  author={J. Rodgers and P. Lam and B. L. Johnson and H. Wang and R. Li and Y. Ru and S. Ko and S. P. Seitz and G. Trainor and P. S. Anderson and R. Klabe and L. Bacheler and B. Cordova and S. Garber and C. Reid and M. Wright and C. Chang and S. Erickson-Viitanen},
  journal={Chemistry & biology},
  year={1998},
  volume={5 10},
  pages={
          597-608
        }
}
BACKGROUND Recent clinical trials have demonstrated that HIV protease inhibitors are useful in the treatment of AIDS. It is necessary, however, to use HIV protease inhibitors in combination with other antiviral agents to inhibit the development of resistance. The daunting ability of the virus to rapidly generate resistant mutants suggests that there is an ongoing need for new HIV protease inhibitors with superior pharmacokinetic and efficacy profiles. In our attempts to design and select… Expand